Tonix Pharmaceuticals
OverviewSuggest Edit
Tonix Pharmaceuticals is a development stage specialty pharmaceutical company, which focuses on the development of pharmaceutical products for the disorders of central nervous system. The Company's lead product candidate, TNX-102 SL or Tonmya, designed as a bedtime treatment for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. Tonix is also developing TNX-601, a clinical candidate at pre-IND (investigational new drug) application stage, designed as a daytime treatment for posttraumatic stress disorder; and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage.
| Type | Public | |
| Founded | 2007 | |
| HQ | New York, US | Map |
| Website | tonixpharma.com | |
| Employee Ratings | More |
Recent NewsAll News
- Tonix Pharmaceuticals to Speak at the Second Chance Digital Impact Recipient Gala
- Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology
- Tonix Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights
- Tonix Pharmaceuticals Announces Update on the Collaborative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA)
Latest Updates
| Employees (est.) (Mar 2019) | 12 | (-14%) |
| Share Price (May 2019) | $2 | (+19%) |
Key People/Management at Tonix Pharmaceuticals
Seth Lederman
Co-Founder, CEO & Chairman
Jessica Edgar Morris
COO
Gregory Sullivan
Chief Medical Officer
Bradley Saenger
CFO
Tonix Pharmaceuticals Office Locations
Tonix Pharmaceuticals has offices in New York, San Diego, Montréal and Dublin
New York, US (HQ)
509 Madison Ave
San Diego, US
4225 Executive Square #250, La Jolla
Montréal, CA
317 1176 Rue Bishop
Dublin, IE
65 Adelaide Rd
Tonix Pharmaceuticals Financials and Metrics
Tonix Pharmaceuticals Revenue
| USD | |
|---|---|
Net income (FY, 2018) | (26.1m) |
EBIT (FY, 2018) | (26.3m) |
Market capitalization (22-May-2019) | 12.4m |
Closing stock price (22-May-2019) | 2.0 |
Cash (31-Dec-2018) | 25.0m |
Tonix Pharmaceuticals's current market capitalization is $12.4 m.
Annual
Quarterly
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
General and administrative expense | 2.0m | 2.2m | 2.9m | 2.9m | 3.0m | 3.3m | 2.3m | 2.1m | 2.1m | 1.9m | 1.8m | 3.9m |
R&D expense | 4.1m | 5.2m | 6.8m | 8.9m | 10.3m | 10.7m | 7.5m | 5.5m | 3.0m | 3.9m | 5.2m | 9.2m |
Operating expense total | 6.0m | 7.4m | 9.7m | 11.8m | 13.3m | 14.0m | 9.8m | 7.6m | 5.1m | 5.8m | 7.0m | 13.1m |
EBIT | (6.0m) | (7.4m) | (9.7m) | (11.8m) | (13.3m) | (14.0m) | (9.8m) | (7.6m) | (5.1m) | (5.8m) | (7.0m) | (13.1m) |
Annual
Quarterly
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 43.9m | 46.2m | 58.2m | 48.7m | 33.0m | 8.4m | 14.9m | 15.6m | 19.9m | 29.3m | 19.3m | 16.7m |
Current Assets | 44.8m | 46.9m | 60.0m | 50.3m | 57.2m | 30.7m | 33.7m | 29.2m | 23.4m | 30.2m | 20.7m | 18.2m |
PP&E | 306.0k | 316.0k | 327.0k | 383.0k | 349.0k | 315.0k | 132.0k | 102.0k | 78.0k | 65.0k | ||
Total Assets | 45.1m | 47.3m | 60.5m | 50.9m | 57.8m | 31.3m | 34.3m | 29.8m | 23.8m | 30.5m | 21.0m | 18.4m |
Annual
Quarterly
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (6.0m) | (7.4m) | (9.7m) | (11.8m) | (13.2m) | (14.0m) | (9.8m) | (31.4m) | (5.1m) | (15.6m) | (6.9m) | (13.0m) |
Depreciation and Amortization | 163.0k | 50.0k | 15.0k | 30.0k | ||||||||
Accounts Payable | 2.0m | 2.8m | 2.4m | 2.1m | 1.9m | (2.1m) | 841.0k | 490.0k | (32.0k) | 342.0k | ||
Cash From Operating Activities | (31.9m) | (14.2m) | (6.8m) | (12.3m) |
| USD | Y, 2018 |
|---|---|
Financial Leverage | 1.1 x |
Tonix Pharmaceuticals News and Updates
May 22, 2019
Tonix Pharmaceuticals to Speak at the Second Chance Digital Impact Recipient Gala
NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will speak at the first annual Second Chance Digital Impact Recipient Gala being held May …
May 21, 2019
Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology
NEW YORK, May 21, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced that it will be presenting pharmacokinetic analyses of TNX-102 SL* in a poster at the American Society of Clinical Psychopharmacology (ASCP) 2019 Annual Meeting. The…
May 13, 2019
Tonix Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights
Phase 3 RECOVERY Trial of Tonmya® for the Treatment of PTSD is Enrolling; Topline Data Expected First Half of 2020 Phase 3 RECOVERY Trial of Tonmya® for the Treatment of PTSD is Enrolling; Topline Data Expected First Half of 2020
April 23, 2019
Tonix Pharmaceuticals Announces Update on the Collaborative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA)
The Termination Does Not Affect Tonix’s Finances or the Ongoing RECOVERY Trial of Tonmya® for the Treatment of PTSD The Termination Does Not Affect Tonix’s Finances or the Ongoing RECOVERY Trial of Tonmya® for the Treatment of PTSD
April 22, 2019
Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya® for the Treatment of Posttraumatic Stress Disorder
Company Will Meet with FDA in June to Address the “Intent to Rescind” Notice Company Will Meet with FDA in June to Address the “Intent to Rescind” Notice
April 19, 2019
Tonix Pharmaceuticals R&D pact with U.S. Army to be terminated 'without cause'
Tonix Pharmaceuticals Holding Corp. disclosed Friday that the U.S. Army Medical Material Development Activity (USAMMDA) is exercising its right to "terminate without cause" the research and development agreement with the company. The termination of the agreement, which Tonix and USAMMDA entered in …
Tonix Pharmaceuticals Blogs
May 08, 2019
Tonix Pharmaceuticals Announces New Board Member, Daniel Goodman, M.D., MBA
NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) today announced the appointment of Daniel Goodman, M.D., MBA to its Board of Directors, effective May 6, 2019.
Dr. Seth Lederman, Chief Executive Officer of Tonix commented, “We are pleas…
March 25, 2019
Tonix Pharmaceuticals to Present at Upcoming Investor Conferences
NEW YORK, March 25, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will present at two upcoming investor conferences.
Details of the Tonix Pharmaceuticals presentations and webcasts are as follows:
Eve…
March 11, 2019
Tonix Pharmaceuticals Enrolls First Participant in the “RECOVERY” Study -- a New Phase 3 Trial of Tonmya® for the Treatment of Posttraumatic Stress Disorder
Topline Data Expected First Half 2020
NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biolo…
March 01, 2019
Tonix Pharmaceuticals Announces Share Repurchase Program
NEW YORK, March 01, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced that its Board of Directors has approved a share repurchase program pursuant to which the Company may repurchase up to $2 million in value of its outstanding comm…
February 04, 2019
Tonix Pharmaceuticals to Present at BIO CEO & Investor Conference
NEW YORK, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present a company overview at the 21st Annual BIO CEO & Investor Conference on F…
January 02, 2019
Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion
NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present a company overview at two investor conferences in January 2019.
In additio…
Tonix Pharmaceuticals Frequently Asked Questions
When was Tonix Pharmaceuticals founded?
Tonix Pharmaceuticals was founded in 2007.
Who are Tonix Pharmaceuticals key executives?
Tonix Pharmaceuticals's key executives are Seth Lederman, Jessica Edgar Morris and Gregory Sullivan.
How many employees does Tonix Pharmaceuticals have?
Tonix Pharmaceuticals has 12 employees.
Who are Tonix Pharmaceuticals competitors?
Competitors of Tonix Pharmaceuticals include Vitality Biopharma, Mylan and Savara Pharmaceuticals.
Where is Tonix Pharmaceuticals headquarters?
Tonix Pharmaceuticals headquarters is located at 509 Madison Ave, New York.
Where are Tonix Pharmaceuticals offices?
Tonix Pharmaceuticals has offices in New York, San Diego, Montréal and Dublin.
How many offices does Tonix Pharmaceuticals have?
Tonix Pharmaceuticals has 4 offices.